An announcement from CSL ( (AU:CSL)) is now available. CSL Limited has announced an update on its ongoing share buy-back program, revealing that a total of 2,773,525 ordinary fully paid securities ...

ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...

CSL Limited has informed the market that 34,261 conditional rights (security code CSLAL) have lapsed after the performance or vesting conditions attached to them were not satisfied or became incapable ...

Fintel reports that on December 8, 2025, JEFFERIES maintained coverage of CSL Limited - Depositary Receipt (OTCPK:CSLLY) with a Buy recommendation. As of December 6, 2025, the average one-year price ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post Could CSL shares outperform the ASX 200 in 2026? appeared first on The Motley ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00. The company’s shares closed yesterday at $174.22.

CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than $500 million per year over the next ...

Australian biotechnology firm CSL Ltd (OTCQX:CSLLY) (OTCQX:CMXHF) is set to downsize its research and development (R&D) division across six international sites, and increase its reliance on external ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...